FY2024 Earnings Forecast for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($4.72) per share for the year, up from their previous estimate of ($4.77). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.73) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($1.05) EPS, FY2025 earnings at ($4.30) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $4.15 EPS and FY2028 earnings at $10.10 EPS.

A number of other research analysts also recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $121.00 price target on shares of Axsome Therapeutics in a report on Thursday, December 12th. Truist Financial upped their price objective on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Robert W. Baird lifted their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Mizuho cut their price target on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, December 31st. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.31.

Axsome Therapeutics Price Performance

AXSM stock opened at $108.85 on Friday. The stock has a market capitalization of $5.27 billion, a price-to-earnings ratio of -16.67 and a beta of 1.04. The stock’s fifty day simple moving average is $93.41 and its 200-day simple moving average is $90.64. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $111.51. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the prior year, the firm posted ($1.32) earnings per share.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of AXSM. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Axsome Therapeutics during the second quarter worth $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Axsome Therapeutics during the second quarter worth about $47,000. R Squared Ltd bought a new position in Axsome Therapeutics in the fourth quarter worth about $64,000. KBC Group NV lifted its holdings in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after acquiring an additional 385 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.